Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

Off-Label, on Target: New Hope for Children with Inflammatory Bowel Disease

Off-label treatments are offering new hope to children battling inflammatory bowel disease (IBD), especially when conventional therapies fall short. A comprehensive new review explores the real-world application of biologics and small molecule drugs originally approved for adults--such as ustekinumab, vedolizumab, upadacitinib, and ozanimod--in pediatric IBD cases. These alternative approaches are showing encouraging results, including higher rates of steroid-free clinical remission and improved disease management in treatment-resistant patients. While these therapies remain technically unapproved for pediatric use, growing evidence suggests they may provide critical relief when other options have been exhausted. The review underscores both the promise and the caution needed when venturing into off-label territory.

August 11, 2025


August 12 2025

August 11 2025

August 10 2025

August 9 2025

August 8 2025

August 7 2025

August 6 2025

August 5 2025

August 4 2025

August 3 2025

August 2 2025

August 1 2025

July 31 2025

July 30 2025